Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Keywords SYS6010 epidermal growth factor receptor antibody drug conjugates non-small cell lung cancer efficacy safety pharmacokinetics Introduction Lung cancer remains the most common cancer worldwide with 2,480,301 new cases and 1,817,172 deaths annually.1 A large proportion of lung cancer patients (48%) are diagnosed with distant metastasis with a corresponding 5-year overall survival (OS) rate of 8%.2 Non-small cell lung cancer (NSCLC) comprises the majority (80%–85%) of lung cancer cases.
Abstract Amyloid transthyretin (ATTR) amyloidosis is a fatal disease caused by the accumulation of misfolded transthyretin proteins. Although knocking down the TTR gene by CRISPR-Cas9 represents a promising strategy for treating ATTR amyloidosis, its efficiency and safety remain to be further investigated. Here, we report a systematic investigation of SpCas9-based TTR editing. Besides the target site, wild-type SpCas9 and the reported variants induced extensive off-target edits.
Our results indicated that the AgNP accumulated in the immune system organs, and mild irritation was observed in the thymus and spleen of animals treated with AgNP, but not with Ag + . The liver and kidneys could be the most affected organs by an acute i.v. dose of AgNP, and significantly increased chromosome breakage and polyploidy cell rates also implied the potential genotoxicity of AgNP.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.